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Platelet-based applications are currently used for the delivery of growth factors and other 
biomolecules as autologous biomaterials in regenerative medicine and cosmetic therapies. 
Many studies have revealed that platelet-based applications such as platelet-rich plasma and 
platelet releasate exhibit beneficial biological effects after a sports injury or trauma when 
administered locally by intramuscularly injections. At present, treatment of the public, patients 
and athletes with platelet-based applications is permitted and regulated by the Food and Drug 
Administration and the World Anti-Doping Agency. Since 2011 the use of autologous platelet-
rich plasma is permitted in competitive sports by the World Anti-Doping Agency, due to the 
lack of evidence in performance enhancement and anabolic effects. However, accumulating 
research has recently shed light on the role of platelet-derived growth factors in wound healing, 
skeletal myogenesis, muscle stem cell function and tissue regeneration. Although any 
ergogenic potential of platelet-rich plasma and platelet releasate on intact skeletal muscle and 
human sports performance remain to be established, novel evidence suggests that platelet-
derived growth factors can modulate muscle, tendon, ligament, protein synthesis/degradation, 
vascularisation, energy utilisation and regenerative capacity in various experimental settings. 
Since platelet-based applications are currently not prohibited, they constitute a tool for 
potential abuse and doping in sports. The aim of this review is to critically discuss and 
assimilate current insights and biological evidence that set the ground for exploitation and 
misuse in competitive sports and develop strategies to combat this. 
 







Introduction. There has been much debate in recent scientific literature both for and against 
the notion that there is an advantageous use of platelet-based applications in musculoskeletal 
adaptations [1,11,29,33,36-38,43,51]. The reason for this particular application to attract such 
consideration relates to the experimental evidence both in vitro and in vivo showing promising 
benefit for skeletal muscle recovery after injury [17,30,31,48,52]. However, the use of platelet-
based applications fails to consistently translate to positive results in clinical trials, especially 
for skeletal muscle injuries [6,36,41,63]. Studies now suggest that the discrepancy in the 
literature may, at least in part, be due to the differing preparation methods between 
laboratories and the clinical setting [1,51]. Beyond the potential benefits of platelets as 
biomaterials for therapeutic purposes, it has previously been speculated that at least 86000 
athletes in the United States have used platelet-rich plasma injections annually [62]. 
In 2011, the World Anti-Doping Agency (WADA) removed autologous platelet-rich plasma 
(PRP) for skeletal muscle, tendon and ligament injections from the prohibition list due to the 
lack of convincing evidence regarding its performance enhancing and anabolic effects. The 
WADA’s current stance on the status of platelet-derived preparations is that PRP does not 
exhibit any potential for performance augmentation other than a possible therapeutic effect. 
Despite the presence of variable cytokines and growth factors in platelet-derived preparations, 
they were removed from the prohibition list.  
In the WADA prohibition lists from 2010-2018 (i.e. section 2 regarding peptide hormones, 
growth factors and related substances), the agency declared a prohibition against the 
individual growth factors; “Growth Hormone, Insulin-like Growth Factor-1, Fibroblast Growth 
Factors, Hepatocyte Growth Factor, Mechano-Growth Factors, Platelet-Derived Growth 
Factor, Vascular-Endothelial Growth Factor”. Interestingly, WADA continued stating that “any 
other growth factor affecting muscle, tendon or ligament protein synthesis/degradation, 
vascularisation, energy utilization, regenerative capacity or fibre type switching; and other 
substances with similar chemical structure or similar biological effect(s)” are also prohibited. 
This was followed in the same section from 2010 by a prohibition against “Platelet-derived 
preparations (e.g. Platelet Rich Plasma, “blood spinning”) administered by intramuscular 
route” for competing athletes [59,60]. However, several of these individual growth factors are 
found in high concentrations in platelet releasates and are still on the WADA’s prohibition list 
when administered independently as refined constituents [52,59,64]. 
Due to the fact that the majority of the above-mentioned growth factors are contained in 
platelet releasate, the aim of this review is to provide current insights in the potential abuse of 
platelet-based applications in competitive sports. We also aim to determine whether there is 
any merit to consider re-establishing PRP and analogues as a performance enhancing 
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applications [13]. The use of PRP and various other platelet-based applications such as 
platelet releasate (defined as an acellular preparation of platelet granule secretions after 
aggregation) have been shown to be beneficial in skeletal muscle injury models 
[6,8,16,17,21,23,24,30-32,39,40,52,54,56]. For this reason, this review will focus on the 2011 
WADA statement that “any growth factors affecting muscle, tendon or ligament protein 
synthesis/degradation, vascularisation, energy utilization, regenerative capacity and other 
substances with similar chemical structure or similar biological effect(s)” are prohibited by 
athletes, and that platelet-based applications may be re-established in this category. 
A PubMed search was conducted to identify articles by using any of the following terms: 
platelet-rich plasma, platelet releasate, doping, skeletal muscle, sports performance, athletes, 
growth factors. Scientific literature was reviewed to identify recent evidence about platelet-
based applications and their effects on the human body taking into account relevant 
experimental evidence. Data from original research papers discussed in this review were 
collected in accordance with the Journal’s Ethical Standards [22]. 
 
Can platelet-based applications be exploited to improve sports performance? 
A study determined the effect of a single intramuscular injection of autologous conditioned 
plasma on the levels of circulating cytokines and growth factors banned by the WADA, in the 
blood of the recipients [49]. This study determined that amongst the levels of Insulin Like 
Growth Factor-1 (IGF-1), Endothelial Growth Factor-1 (EGF-1), Platelet-Derived Growth 
Factor-AB, -BB (PDGF-AB, -BB), Fibroblast Growth Factor (FGF), Vascular-Endothelial 
Growth Factor-1 (VEGF-1) and Transforming Growth Factor-B1, or -B2 (TGF-B1, -B2), only 
TGF-B2 showed a significant increase in circulating blood 3 hours and 24 hours post-injection. 
This may increase the potential for fibrosis according to the authors. If intramuscular injections 
of PRP do not increase banned substances in the circulatory system, this impedes methods 
of Anti-doping detection. Unlike blood doping, however, platelet-based applications are 
autologous, and are supposed unlikely to be ergogenic [35]. One may argue that concentrating 
a substance (e.g. PRP) by removal, refinement and re-introduction to a specific location, such 
as intramuscular injections, may augment tissue function without being detected in the 
circulatory system.  
Opinions regarding the removal of PRP from the WADA prohibition list have been expressed 
in detail previously [14,18]. It has been argued that the unbound half-life of IGF-1 (10 minutes) 
would not be able to exert systemic effects, and therefore, any potential benefits are limited to 
the area of injection. The same study also states that the concentration of IGF-1 has to be 500 
times higher than that found in PRP in order to exert systemic anabolic effects [14]. However 
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direct evidence that platelet-based applications are ergogenic in uninjured skeletal muscle is 
still lacking, providing further grounds for the removal of PRP from the WADA prohibition list 
in 2011 [18,59]. A later publication looked at the systemic effects of PRP in circulation after 
intra-tendinous injections, using similar PRP preparation methods as Creaney and Hamilton 
in 2008. This study reported that increased levels of the constituents banned by WADA were 
detected systemically after injection of PRP [59,62]. In fact, serum IGF-1, VEGF, and bFGF 
levels were significantly elevated after PRP injection, associated with an ergogenic effect of 
PRP, exclaiming that VEGF could be used as a potential marker for PRP doping. 
It is important to emphasise the fact that taking PRP off the prohibition list does not restrict the 
athletes from using higher concentrations of platelet-released growth factors and apply them 
more frequently. As of yet, there has been no standardised clinical preparation method for 
PRP, indicating that the system is susceptible to being abused in the context of sports 
performance. Moreover, additional platelet-based applications can be utilised, such as platelet 
releasate, platelet lysate, platelet-rich fibrin, leukocyte-rich PRP to further customise and 
optimise the preparation of PRP for use in athletic competition. Previous studies have 
attempted to customise PRP for further benefits in skeletal muscle recovery, such that by 
removing TGF-β it may avoid fibrosis and inflammation [34]. Furthermore, we have recently 
shown that platelet releasate increases the proliferation of myoblasts with a linear correlation 
to the concentration of platelets used [52]. However, the impact of platelet releasate in muscle 
stem cell function and myogenesis in highly trained healthy individuals such as athletes 
remains to be determined. 
 
Recent evidence for platelet-based applications to remodel skeletal muscle and 
potentially increase sports performance. There has been recent robust evidence that 
platelet-based applications positively affect myoblast proliferation, early inflammatory 
response, myogenic regulatory factors, regeneration time and muscle fibre hypertrophy with 
a decrease in pain, claudication score, oxidative stress and time-to recovery [6-
9,12,16,17,21,23,24,30-32,34,40,44-46,54,56,57,63]. In particular, platelet releasate has 
been shown by independent groups to increase skeletal muscle regeneration in vivo 
[52,56,57]. This supports the notion that the positive effect on skeletal muscle is derived from 
platelet granule secretions as opposed to the plasma or cell-to-cell contact. With this being 
the case, the potential to concentrate the growth factors and increase the dose in an 
autologous or allogeneic manner is a matter of concern that could be abused by athletes. 
Growth factors directly derived from platelet-based applications are known to affect other 
tissues and this is in conflict with the WADA statement that prohibits the use of “any growth 
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factor(s) affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, 
energy utilization, regenerative capacity”. As outlined in previous papers, platelet-based 
applications affect tendon and skeletal muscle tissue (see figure 1) and cellular 
vascularisation, regenerative capacity and protein synthesis and skeletal muscle energy 
utilisation [3,9,17,50-52,57,58]. 
The main argument against using platelet based applications is typically due to the lack of 
detectable growth factors in the circulatory system after intramuscular injection [14]. Although 
this is a prominent argument whereby platelet-based applications may lack systemic effects; 
the experimental evidence suggests a localised injection through ultrasound guidance is quite 
effective at regeneration [15,53]. It is indeed important to speed up recovery and injury in 
sports and orthopaedics; however, the major lacking evidence is the effect on uninjured 
skeletal muscle. Moreover, in vivo studies looking at non-regenerating myofibres remain to be 
conducted to obtain a better understanding whether platelet-based applications are effective 
in increasing performance. Additionally, platelet concentration typically takes up to seven days 
to return to baseline in the blood after donation with prolonged storage of platelet releasate, 
supra-physiological levels of growth factors can be achieved [55]. 
Interestingly, one study looking at uninjured skeletal muscles from racing horses showed an 
increase in embryonic and type I myosin heavy chain mRNA expression two and seven days 
after PRP injection, respectively [20]. Whether this can be translated to muscle fibre growth or 
hyperplasia, was not examined in that particular study and the physiological significance of 
this finding remains to be established. To the best of our knowledge this is the only report we 
could identify on PubMed using PRP into intact muscle, where a potentially beneficial effect 
was observed.  
A recent article has shown how application of platelet releasate can alter skeletal muscle stem 
cell fate and drive myogenesis [52]. Myogenic regulatory factors such as MyoD expression 
have been shown to be altered on myofibres from mice ex vivo after platelet releasate 
application in a dose-dependent manner [30,52]. Both Pax7 and MyoD are important markers 
for skeletal muscle stem cells. Pax7 is expressed in quiescent and activated cells, however 
MyoD is expressed in activated and proliferating cells [67]. Loss of Pax7 in MyoD-positive cells 
is seen after application of platelet releasate, causing an enhanced commitment to 
differentiation, without sacrificing the pool of Pax7-positive stem cells returning to quiescence 
[30,52]. Since regular exercise training drives skeletal muscle functional adaptations by 
regulating muscle stem cell function, the above recent findings raise concerns about the 
WADA 2018 prohibition list on peptide hormones, growth factors, related substances, and 
mimetics and/towards potential abuse in sports [26,61]. However, it becomes apparent that 
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further studies into intact muscle in vivo need to be carried out before any assumption can be 
made about whether platelet-based applications are beneficial for athletes.   
 
The Food and Drug Administration’s stance on platelet-based applications. Although 
platelet-based applications are not on the United States’ Food and Drug Administration’s 
(FDA) banned substance list, there are rules and regulations for commercially using them 
cosmetically and therapeutically. In terms of using PRP for sports-related or therapeutic 
augmentations, there are many legalities and such as that clinicians are made to maintain 
records of use and effects have a biologics licence and to keep up-to-date with the current 
evidence in the field [5]. These restrictions, in turn, help regulate safety and consistency and 
keep record of PRP procedures. PRP is considered a “biologic”, or biological product by the 
FDA. Biologics are regulated by the FDA’s centre for biologics evaluation and research. 
However, the use of autologous growth factors had not been specifically considered by 
WADA, prior to 2010 [4,35]. The ability, however difficult and expensive, to currently treat the 
public, patients and athletes with PRP and platelet-rich products is perfectly acceptable under 
FDA and WADA regulations. This leaves the possibility for the application of concentrated 
supra-physiological platelet-based applications, or frequently used intramuscular injections to 
be potentially abused. Supra-physiological levels of platelets used to make platelet releasate 
have recently been shown to dose-dependently upregulate myoblast proliferation in vitro, 
which may contribute to a faster recovery after training or exercise, similar to anabolics [52].  
 
Safety of platelet-based applications for use by athletes. Despite the plausible potential 
for athletes to abuse platelet-based applications to manipulate sports performance, another 
crucial factor to consider is the safety of application. There is currently increasing evidence in 
the literature as to whether platelet-based applications affect cellular senescence, apoptosis, 
reactive oxygen species and mutagenesis. Some promising articles addressing these aspects 
show a reduction in apoptosis of in vivo injured skeletal muscle [56]. Similarly, cellular survival 
has been shown to be increased with platelet-based applications in vitro [46]. Platelet-based 
applications are known to be pro-proliferative in many tissues and to induce angiogenesis, 
which has sparked interest in their effects on cancers. It has recently been shown that platelet 
releasate causes breast cancer growth and angiogenesis via VEGF signalling [25]. In fact, 
platelets are known to drive cellular proliferative signals, cell survival, metastasis and 
angiogenesis [19]. This microenvironment may be potentially harmful in already existing 
cancers, however platelet-based applications are argued to be autologous and non-harmful 
as they do not induce mutagenesis [42]. On the other hand, clinical trials report an effective 
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and safe outcome to using platelet-based applications for multiple treatments with no 
observed side effects [6,12,28,63,68]. Additionally, allogeneic platelet-rich plasma has 
recently been deemed safe for osteoarthritis patients according to a human pilot study [10]. 
This suggests that PRP may be a safe treatment even if non-autologous, although this remains 
to be established in large scale studies. At present, the WADA does not distinguish between 
the use of autologous and allogeneic PRP [2]. Subsequently, a potential route towards 
performance manipulation cannot be ruled out, such that master-class athletes are currently 
not restricted from using allogenic platelet-rich plasma from young athletes [2]. A recent study 
has established a differential profile of platelet-rich plasma-contained growth factors amongst 
individuals in terms of age and sex, showing higher levels of growth factors (e.g. IGF-1) and 
lower levels of inflammatory and fibrosis-inducing cytokines (e.g. TGF-β) in young males [66]. 
Consequently, with allogeneic PRP becoming a safe and viable option for patient treatment, 
and no ban on its use in athletes, the risk of exploitation is not prohibited.  
To-date, there is a noticeable difficulty of testing for autologous platelet-based applications. 
Potential PRP involvement in altering the biological passport of an athlete could be a way of 
detecting platelet-related abuse in sporting applications, but remains to be established. The 
option for athletes to use their own platelet’s innate ability to induce regeneration is receiving  
clinical attention and could potentially be already exploited for performance manipulation [62]. 
Similarly, allogeneic platelet-based applications constitute a new therapeutic tool for several 
diseases, that can be  enriched by recombinant growth factors and their abuse in sports is 
unavoidable [2].  
 
Conclusion 
In this review, we aimed to discuss current insights and biological evidence that set the ground 
for exploitation and misuse in competitive sports and provide reasoning that may help to 
develop strategies to combat this. With studies reporting no increase in systemic levels of 
growth factors in the blood after intra-muscular PRP injections, there is reasonable merit to 
not consider PRP a banned substance. However, with more recent studies emerging, 
additional consideration needs to be deliberated, such as manipulation, customisation and 
concentration of PRP preparation methods that can be abused by athletes. Allogeneic 
applications from healthier and younger individuals that were overlooked previously in terms 
of performance manipulation may require re-evaluation. The 2011-2018 WADA prohibition 
lists declare that any substance that increases muscle, tendon or ligament protein 
synthesis/degradation, vascularisation, energy utilisation or regenerative capacity is banned. 
As current evidence has shown that such methods strongly impact skeletal muscle, tendon, 
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ligament and orthopaedics in terms of regeneration and potential for sports performance, the 
risk to abuse platelet-based applications remains valid. 
 
Future perspectives 
There is limited evidence on whether platelet-based applications can improve sports 
performance and/or reprogramme skeletal muscle transcriptional signature in healthy, non-
injured individuals. Therefore, more studies are needed to assess experimentally whether 
such platelet-based approaches are able to improve muscle strength, and/or increase muscle 
mass, and/or increase endurance, and/or increase athletic performance, and/or affect 
recovery time, and/or affect protein synthesis, and/or alter redox homeostasis. To this aim, it 
is essential to establish and further develop techniques in order to detect abuse of platelet-
based applications in competitive sports. For example, VEGF has been previously suggested 
as a marker for PRP doping in the blood [62]. 
Knowledge in the field of platelet-based applications affecting skeletal muscle, ligament and 
tendon is continuously accumulating. Despite the absence of direct evidence linking platelet 
applications with increase sports performance, current evidence suggests that platelet-rich 
plasma drives skeletal myogenesis in vitro, ex vivo and accelerates regeneration in vivo. This 
falls within the current doping definition regarding manipulations of regenerative capacity and 
begs the question whether platelet-based applications have to be reconsidered as prohibited 




Figure 1. A schematic depicting clinical and pre-clinical evidence for the beneficial effects of 
platelet-based applications on different areas of the body for tendon, ligament and skeletal 
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